Cover Image
市場調查報告書

男性性腺功能低下症 : 開發平台分析

Male Hypogonadism - Pipeline Review, H2 2018

出版商 Global Markets Direct 商品編碼 232815
出版日期 內容資訊 英文 101 Pages
訂單完成後即時交付
價格
Back to Top
男性性腺功能低下症 : 開發平台分析 Male Hypogonadism - Pipeline Review, H2 2018
出版日期: 2018年07月17日 內容資訊: 英文 101 Pages
簡介

男性性腺功能低下症的主要症狀、有倦怠感、身體的發熱、不孕、肌肉量的減少、骨質疏鬆症。男性性腺功能低下症容易發病的環境、有HIV/AIDS、柯林菲特氏症、卡爾曼氏症候群、睪丸的負傷、睡眠呼吸中止症等。

本報告提供男性性腺功能低下症治療藥的開發情形的相關調查、開發中產品的概要、臨床實驗的各階段的產品概要、主要企業簡介、藥物簡介、開發中產品的最新趨勢等。

簡介

  • 調查範圍

男性性腺功能低下症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

男性性腺功能低下症:企業開發中的治療藥

男性性腺功能低下症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

男性性腺功能低下症:企業開發中的產品

男性性腺功能低下症治療藥的開發企業

  • Antares Pharma, Inc.
  • BIOCAD
  • Clarus Therapeutics, Inc.
  • Diurnal Limited
  • EndoCeutics, Inc.
  • Ferring International Center S.A.
  • Forendo Pharma Limited
  • Lipocine Inc.
  • M et P Pharma AG
  • Merck & Co., Inc.
  • Mereo Biopharma Group Limited
  • Millennium Pharmaceuticals, Inc.
  • Monosol Rx, LLC
  • Pantarhei Bioscience BV
  • Repros Therapeutics Inc.

男性性腺功能低下症:治療藥的評估

  • 單劑產品
  • 各標靶
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BGS-649
  • corifollitropin alfa
  • enclomiphene
  • fispemifene
  • follitropin alfa
  • Kisspeptin-10
  • Libidua
  • LPCN-1111
  • MSS-722
  • T-2
  • TAK-448
  • TBS-1
  • Testavan
  • testosterone
  • testosterone
  • testosterone
  • testosterone
  • testosterone enanthate
  • testosterone undecanoate
  • testosterone undecanoate
  • testosterone undecanoate
  • testosterone undecanoate
  • testosterone undecanoate

男性性腺功能低下症:最近的開發平台趨勢

男性性腺功能低下症:暫停中的計劃

男性性腺功能低下症:開發中止的產品

男性性腺功能低下症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10635IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Male Hypogonadism - Pipeline Review, H2 2018, provides an overview of the Male Hypogonadism (Male Health) pipeline landscape.

Male hypogonadism is a condition in which the body doesn't produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles and untreated sleep apnea. Treatment includes hormone replacement.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Male Hypogonadism - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Male Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 2, 4, 5, 2, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Male Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Male Hypogonadism (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Male Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Male Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Male Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Male Hypogonadism (Male Health)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Male Hypogonadism (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Male Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Male Hypogonadism - Overview
    • Male Hypogonadism - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Male Hypogonadism - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Male Hypogonadism - Companies Involved in Therapeutics Development
    • Antares Pharma Inc
    • Clarus Therapeutics Inc
    • Diurnal Group Plc
    • EndoCeutics Inc
    • Ferring International Center SA
    • Lipocine Inc
    • M et P Pharma AG
    • Medlab Clinical Ltd
    • Merck & Co Inc
    • Mereo Biopharma Group Plc
    • Repros Therapeutics Inc
    • TesoRx Pharma LLC
    • Viramal Ltd
  • Male Hypogonadism - Drug Profiles
    • chorionic gonadotropin ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • corifollitropin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • enclomiphene citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IAS-167A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Kisspeptin-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • leflutrozole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • leuprolide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Libidua - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone enanthate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone propionate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone undecanoate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone undecanoate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone undecanoate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone undecanoate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone undecanoate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VERU-722 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Male Hypogonadism - Dormant Projects
  • Male Hypogonadism - Discontinued Products
  • Male Hypogonadism - Product Development Milestones
    • Featured News & Press Releases
      • Jun 14, 2018: Acerus Announces Approval of NATESTO in South Korea
      • May 03, 2018: Aytu BioScience Provides Update on Natesto
      • Apr 05, 2018: Acerus to Present at the Next CHINABIO Partnering Forum
      • Apr 05, 2018: Antares Pharma Provides Update on XYOSTED
      • Mar 27, 2018: Antares Pharma Announces XYOSTED Regulatory Update
      • Mar 20, 2018: Aytu BioScience Presents New Research Findings for Natesto at the Endocrine Society's 100th Annual Meeting
      • Mar 19, 2018: Mereo BioPharma Announces Positive Top-Line Results from Phase 2b Study of BGS-649 for the Treatment of Hypogonadotropic Hypogonadism in Obese Men
      • Mar 15, 2018: Ferring announces positive outcome of European Decentralised Procedure for Testavan, a treatment for men with hypogonadism
      • Feb 02, 2018: Acerus Pharma's NATESTO to Be Listed for Public Reimbursement in Quebec, Building on Strong 28% Increase in Natesto's Canadian Prescriptions in Q4 2017
      • Jan 26, 2018: Repros Announces Negative Opinion From the EMA for Enclomiphene
      • Jan 16, 2018: Antares Pharma Provides XYOSTED Regulatory Update 2018
      • Dec 21, 2017: Antares Pharma Provides Regulatory Update on XYOSTED
      • Dec 15, 2017: Repros Therapeutics Receives Feedback Following an Oral Explanation with the European Medicines Agency
      • Dec 06, 2017: Acerus Enters into Loan Facility to Support Anticipated Product Launch and Sales and Marketing Initiatives
      • Nov 30, 2017: Acerus Secures CDN$1.6M of New NATESTO Orders from Its U.S. Licensee Aytu Bioscience
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Male Hypogonadism, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Male Hypogonadism - Pipeline by Antares Pharma Inc, H2 2018
  • Male Hypogonadism - Pipeline by Clarus Therapeutics Inc, H2 2018
  • Male Hypogonadism - Pipeline by Diurnal Group Plc, H2 2018
  • Male Hypogonadism - Pipeline by EndoCeutics Inc, H2 2018
  • Male Hypogonadism - Pipeline by Ferring International Center SA, H2 2018
  • Male Hypogonadism - Pipeline by Lipocine Inc, H2 2018
  • Male Hypogonadism - Pipeline by M et P Pharma AG, H2 2018
  • Male Hypogonadism - Pipeline by Medlab Clinical Ltd, H2 2018
  • Male Hypogonadism - Pipeline by Merck & Co Inc, H2 2018
  • Male Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H2 2018
  • Male Hypogonadism - Pipeline by Repros Therapeutics Inc, H2 2018
  • Male Hypogonadism - Pipeline by TesoRx Pharma LLC, H2 2018
  • Male Hypogonadism - Pipeline by Viramal Ltd, H2 2018
  • Male Hypogonadism - Dormant Projects, H2 2018
  • Male Hypogonadism - Discontinued Products, H2 2018

List of Figures

  • Number of Products under Development for Male Hypogonadism, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products by Targets, H2 2018
  • Number of Products by Stage and Targets, H2 2018
  • Number of Products by Mechanism of Actions, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018
Back to Top